Ginkgo Bioworks issued a massive revenue warning, causing shares to drop and raising concerns about the company's future. Q1 revenues were significantly below expectations, with a decline in both ...

The company also wants to terminate and sublease extra space. After a disappointing first quarter earnings, Ginkgo Bioworks Holdings Inc. plans to reduce its labor expenses at least 25% ...

After lackluster first-quarter earnings, Ginkgo Bioworks said it will slash labor expenses by at least 25 percent, which will include an unspecified number of job cuts. Total revenue in the first ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Ginkgo is embarking on a cost-cutting plan that could pave the path to profitability and share performance. The main bear case against Ginkgo is there's no compelling reason to buy the stock right ...

Shares of Ginkgo Bioworks have been beaten severely in response to heavy financial losses. The company's cell foundry could disrupt the biopharmaceutical manufacturing industry. Ginkgo Bioworks ...

The bad news keeps coming for Ginkgo Bioworks. Four days after it announced it was slashing labor costs by at least 25 percent, the once-high-flying Boston life sciences firm said it had received ...

Ginkgo Bioworks' first quarter earnings were weak, with revenue and guidance falling well short of expectations. The company is shifting its business model away from ownership of IP and ...

Ginkgo's Class A Common Stock continues to trade on the NYSE BOSTON, May 13, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo" or the "Company"), which is building the ...

Ginkgo Bioworks reports quarterly sales of $38 million which missed the analyst consensus estimate of $46.044 million by 17.47%. "Ginkgo is an increasingly important part of the biotech ecosystem ...